ACADIA Pharmaceuticals 2025 Q4 Earnings: $20M IRA Estimate Breakdown 2022–2025

Analysis of the $20 Million IRA Change in Estimate for NUPLAZID and Its Year-by-Year Allocation (2022–2025) and Cash Impact

ACADIA Pharmaceuticals reported a $20 million nonrecurring change in estimate related to the Inflation Reduction Act (IRA) rebate accruals for NUPLAZID, driven by higher Medicare volume than previously accrued for, based on invoices received in fiscal year 2025 from CMS. This change in estimate adjusted gross-to-net sales, reducing net sales by $20 million in total over the years 2022 through 2025 ¹².

Year-by-Year Breakdown of $20 Million Change in Estimate

• The $20 million adjustment is a cumulative correction to the IRA rebate accruals for the period covering 2022, 2023, 2024, and 2025, apportioned to the years when the Medicare volume related to NUPLAZID occurred.
• While the company did not explicitly present the exact dollar allocation by calendar or fiscal year in the excerpts, it stated the adjustment "is apportioned to the years in which the applicable NUPLAZID net sales volumes occurred" and described the overall correction as a modest impact on net sales over this 4-year period ¹.
• Reference to the "adjusted NUPLAZID net sales" shows the impact on reported sales was reflected retroactively for comparability, yielding $692 million in adjusted net sales for full-year 2025 versus GAAP net sales of $680 million (implying adjustments that smooth the $20 million impact across these periods) ¹².

Cash vs. Noncash Impact

• Cash payments: In Q4 2025, ACADIA paid their first IRA invoice of $108 million covering the first 2 years of the program (likely 2023 and 2024 or covering earlier Medicare rebates). The total cash flow impact for the year, which includes this payment plus additional accruals, was approximately $30 million net outflow during 2025 ³.
• Noncash accounting adjustments: The $20 million change in estimate itself is a noncash adjustment to gross-to-net revenues (effectively an accounting estimate to align accrued rebates with actual Medicare volume data). It reflects more precise revenue recognition rather than immediate cash outflows ³¹.
• The company emphasized the $108 million payment (cash) went out in the quarter and year, whereas the $20 million adjustment affects the accounting estimate and net sales recognition retrospectively ³.

Summary Table

• The $30 million net cash flow in 2025 represents cash paid for the prior periods and current year rebates, including the large invoice received and paid in Q4 2025 ³.
• No further immediate additional changes or invoices were disclosed as expected beyond those reconciled in this adjustment, indicating this $20 million adjustment may not recur ³.

---

Analytical Conclusions

• The $20 million accounting change in estimate for the IRA rebate accrual was a nonrecurring adjustment reflecting higher-than-expected Medicare volumes in prior years 2022–2025.
• The adjustment was apportioned back to those years on a retrospective basis for accurate revenue recognition and comparability but does not represent new cash payments for those years.
• Cash outflows related to the IRA rebates mostly crystallized in 2025, including the initial $108 million invoice payment (covering first 2 years) plus ongoing accruals, yielding an approximate $30 million net cash impact in the year ³.
• This adjustment and cash impact reflect an operational reconciliation to newly received CMS volume data, enabling more accurate gross-to-net reporting for NUPLAZID sales and clarifying prior accrual underestimates.
• Management indicated confidence that this adjustment is nonrecurring and reflective of catching up to CMS reporting, thereby normalizing future rebate accruals ³.

---

References

• $20M IRA rebate accrual change and year allocation described as a 4-year adjustment apportioned to sales volumes in those years, with $30M net cash outflow in 2025 including $108M invoice payment for first 2 years ³¹.
• Adjusted versus reported net sales for NUPLAZID with $20M adjustment smoothing impact over the period 2022-2025 ¹².

---

In summary, ACADIA allocated the $20 million IRA rebate accrual change as a noncash adjustment across fiscal years 2022–2025, reflecting prior underestimated Medicare volumes, while the principal cash payments and resulting $30 million net cash outflow were realized in 2025 when the first invoices were paid.